Letter to the Editor

Squamous Cell Carcinoma of the Oral Cavity Following Breast Cancer Treatment

Authors: Gang Ye, MD, Gary V. Burton, MD, Cherie-Ann O. Nathan, MD, Federico L. Ampil, MD

Abstract

Early diagnosis and combined modality of treatment have significantly improved the survival of breast cancer patients. Most patients will die of etiologies other than breast cancer, which may include second primary malignancies (SPM). We report here two patients who developed squamous cell carcinoma of the oral cavity following treatment of primary breast cancer with chemotherapy and radiotherapy. The possible association of adjuvant therapy with SPM is discussed.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Rubino C, de Vathaire F Shamsaldin A, et al. Radiation dose, chemotherapy, hormonal treatment and risk of second cancer after breast cancer treatment. Br J Cancer 2003;89:840–846.
 
2. Galper S, Gelman R, Recht A, et al. Second nonbreast malignancies after conservative surgery and radiation therapy for early-stage breast cancer. Int J Radiat Oncol Biol Phys 2002;52:406–414.
 
3. Tanaka H, Tsukuma H, Koyama H, et al. Second primary cancers following breast cancer in the Japanese female population. Jpn J Cancer Res 2001;92:1–8.
 
4. Silverman S Jr. Demographics and occurrence of oral and pharyngeal cancers. The outcomes, the trends, the challenge. J Am Dent Assoc 2001;132:7S–11S
 
5. Smith RE, Bryant J, DeCillis A, et al. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol 2003;21:1195–1204.